Scientists develop one-product-fits-all immunotherapy for pancreatic cancer

Pancreatic cancer is among the deadliest forms of cancer, with most patients diagnosed after the disease has already spread throughout the body. The five-year survival rate for metastatic cases hovers around 2–3%, and median survival is often measured in months rather than years.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup